Intellia Therapeutics, Inc. (NTLA)

NASDAQ: NTLA · IEX Real-Time Price · USD

22.15

-0.32 (-1.42%)

At close: Jul 2, 2024, 4:00 PM

21.70

-0.45 (-2.03%)

After-hours: Jul 2, 2024, 7:35 PM EDT

Intellia Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2015
Net Income	-481.19	-474.19	-267.89	-134.23	-99.53	Upgrade
Depreciation & Amortization	8.98	7.57	6.89	6.31	5.59	Upgrade
Share-Based Compensation	134.05	91.4	47.01	19.9	15.09	Upgrade
Other Operating Activities	-55.92	41.93	-11.04	58.11	-24.39	Upgrade
Operating Cash Flow	-394.09	-333.29	-225.03	-49.91	-103.24	Upgrade
Capital Expenditures	-13.99	-13.41	-12.76	-3.59	-6.79	Upgrade
Acquisitions	0	-44.83	-3	0	0	Upgrade
Change in Investments	-17.36	218.55	-535.02	-210.9	31.97	Upgrade
Investing Cash Flow	-31.35	160.31	-550.78	-214.49	25.18	Upgrade
Share Issuance / Repurchase	126.39	580.31	734.66	370.22	75.34	Upgrade
Other Financing Activities	3.93	2.65	2.02	1.56	1.09	Upgrade
Financing Cash Flow	130.32	582.96	736.69	371.78	76.43	Upgrade
Net Cash Flow	-295.11	409.98	-39.12	107.38	-1.63	Upgrade
Free Cash Flow	-408.07	-346.7	-237.79	-53.5	-110.03	Upgrade
Free Cash Flow Margin	-1124.94%	-665.17%	-719.41%	-92.25%	-255.28%	Upgrade
Free Cash Flow Per Share	-4.60	-4.50	-3.35	-0.96	-2.33	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).